US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Birth Control

2,809.53

+37.321.35%

Number of Gainers:4

Number of Losers:1

Number of Flat:- -

PE:- -

High:2,843.20

Open:2,773.64

Low:2,762.59

Close:2,772.21

Volume:8.62M

Turnover:176.88M

Market Cap:44.92B

Float Cap:41.95B

Loading ...

MannKind Corporation - Selling Stockholders May Offer up to 12,853,470 Shares Including 2,412,632 Warrant Shares - SEC Filing

THOMSON REUTERS

Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate

Simply Wall St.

TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer

Femasys announces FDA approval of FemBloc modular premarket approval application

Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome

MT Newswires Live

Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device

Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States

THOMSON REUTERS

Femasys - Fembloc Approved for Marketing in Europe and Select International Markets

THOMSON REUTERS

Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding

DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List

THOMSON REUTERS

DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List

Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares

Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share

Teva price target raised to $42 from $40 at Barclays

Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)

Femasys Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Evofem Q2 FY26 Net Loss Widens to $8.55 Million; Net Product Sales Fall 45% to $2.63 Million

Femasys Q2 Net Loss Narrows 2.55% to $4.47 Million; Net Sales Drop 18.9% to $331,827

Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update

THOMSON REUTERS

Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK4584/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4584","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","market":"US","secType":"PLATE","nameCN":"Birth Control","latestPrice":2809.5261,"timestamp":1787342399999,"preClose":2772.205,"halted":0,"volume":8615466,"delay":0,"changeRate":0.013463,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":37.321045,"latestTime":"08-21 16:00:00 EDT","open":2773.6416,"high":2843.2031,"low":2762.586,"amount":176883492.694548,"amplitude":0.029081,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":5.743837,"peRate":70.810459,"turnoverRate":0.005996,"increases":4,"decrements":1,"flats":0,"marketCap":44921179196,"floatMarketCap":41949345425},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4584\",,,,,undefined,":{"symbol":"BK4584","high":2843.2031,"amplitude":0.029081,"preClose":2772.205,"low":2762.586,"pbRate":"5.743837","latestPrice":2809.5261,"volume":8615466,"delay":0,"open":2773.6416,"prevYearClose":2379.9924,"prevWeekClose":2762.5803,"prevMonthClose":2636.2712,"prevQuarterClose":2562.5076,"fiveDayClose":2762.5803,"twentyDayClose":2335.9458,"sixtyDayClose":2579.5955,"secType":"PLATE","market":"US","turnoverRate":0.005996,"peRate":70.810459,"marketCap":44921179196,"floatMarketCap":41949345425,"timestamp":1787342399999,"nameCN":"Birth Control"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4584\",,,,undefined,":{"bkCode":"BK4584","up":4,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4584\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661529765","title":"MannKind Corporation - Selling Stockholders May Offer up to 12,853,470 Shares Including 2,412,632 Warrant Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2661529765","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661529765?lang=en_us&edition=fundamental","pubTime":"2026-08-22 04:07","pubTimestamp":1787342833,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nFWN44I0XT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4584","MNKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660633238","title":"Teva (TEVA) Wins FDA Priority Review For Pediatric Tourette Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2660633238","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660633238?lang=en_us&edition=fundamental","pubTime":"2026-08-20 21:30","pubTimestamp":1787232636,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries (NYSE:TEVA) announced that the U.S. FDA has accepted its New Drug Application for ecopipam for pediatric Tourette syndrome with Priority Review status.\nEcopipam is described by Teva as a first in class therapy candidate targeting children and adolescents with Tourette syndrome, an area where no new treatments have been approved in over a decade.\nThe filing is backed by positive late stage clinical trial data and adds another potential branded medicine to Teva's...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-teva-wins-fda-priority-review-for-pediatric-tourette-dr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/teva-teva-wins-fda-priority-review-for-pediatric-tourette-dr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4584","LU1983299246.USD","BK4007","TEVA","BK4566","BK4559","BK4585","BK4557","BK4588","LABU","BK4596","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660077421","title":"TEVA Stock Climbs as 50-Year-Long Tourette Syndrome Drug Breakthrough Moves Closer","url":"https://stock-news.laohu8.com/highlight/detail?id=2660077421","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660077421?lang=en_us&edition=fundamental","pubTime":"2026-08-19 23:16","pubTimestamp":1787152563,"startTime":"0","endTime":"0","summary":"Shares in Teva Pharmaceutical Industries ($TEVA) were healthier today after a potential 50-year-long breakthrough treatment for Tourette syndrome m...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/teva-stock-climbs-as-50-year-long-tourette-syndrome-drug-breakthrough-moves-closer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/teva-stock-climbs-as-50-year-long-tourette-syndrome-drug-breakthrough-moves-closer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4559","TEVA","BK4585","LU1983299246.USD","BK4007","BK4584","BK4557","BK4588","LU2324357040.USD","BK4566","BK4596"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660252964","title":"Femasys announces FDA approval of FemBloc modular premarket approval application","url":"https://stock-news.laohu8.com/highlight/detail?id=2660252964","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660252964?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:16","pubTimestamp":1787145413,"startTime":"0","endTime":"0","summary":"Femasys (FEMY) announced that the FDA has approved the company’s modular premarket approval application pathway for FemBloc, its investigational no...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/femasys-announces-fda-approval-of-fembloc-modular-premarket-approval-application-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BMED","FRTY","FEMY","PINK","BK4539","IBB","MRNX","GDOC","BK4585","TBXU","IYH","RSPH","BBP","IDNA","BK4588","LFSC","NVIB","GNMX","PSCH","BK4082","MRNY","BK4584","SYNB","IEIH","MEDI","LABU","XLVX","TECB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660624425","title":"Teva Pharmaceuticals Says FDA Accepts Ecopipam Filing for Tourette Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2660624425","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660624425?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:10","pubTimestamp":1787145009,"startTime":"0","endTime":"0","summary":"Teva Pharmaceutical Industries'  US affiliate Teva Pharmaceuticals said Wednesday the US Food and Drug Administration has accepted its new drug application for ecopipam to potentially treat children with Tourette syndrome.The regulator has set a target action date for late in Q1 of 2027, the company said.The application is supported by phase 2b and phase 3 data, which showed a reduction in tic severity and sustained efficacy, Teva said.Teva Pharmaceutical Industries shares were up 1.8% in premarket activity Wednesday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4566","BK4588","BK4557","BK4584","TEVA","LABU","LU2324357040.USD","BK4559","LU1983299246.USD","BK4007","BK4596","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660425838","title":"Femasys Says FDA OKs Modular PMA Pathway for FemBloc Birth Control Device","url":"https://stock-news.laohu8.com/highlight/detail?id=2660425838","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660425838?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144434,"startTime":"0","endTime":"0","summary":"Femasys says FDA OKs modular PMA pathway for FemBloc birth control deviceFDA cleared Femasys to use a modular PMA submission pathway for FemBloc, its investigational non-surgical permanent birth contr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nNDL8HTqC8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00BN0W2T93.GBP","LU2210150020.SGD","IE00BKPKM429.USD","SG9999014039.USD","BK4588","FEMY","BK4082","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4112","LU2095319765.USD","SG9999014005.SGD","NDAQ","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4584","IE00BQXX3D17.EUR","IE00BQXX3F31.USD","LU0314104364.USD","IE00BN0W2V16.EUR","BK4585","IE00BGHQF748.EUR","BCDF","IE00BN0W2W23.USD","BK4539","LU2210149790.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660803425","title":"Femasys - FDA Approves Modular Pma Pathway for Fembloc in the United States","url":"https://stock-news.laohu8.com/highlight/detail?id=2660803425","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660803425?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144400,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA61CLCY:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FEMY","BK4584","BK4539","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660542580","title":"Femasys - Fembloc Approved for Marketing in Europe and Select International Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2660542580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660542580?lang=en_us&edition=fundamental","pubTime":"2026-08-19 21:00","pubTimestamp":1787144400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260819:nTUA61CLCY:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4584","BK4539","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660646700","title":"Daré Bioscience DARE-HPV Program Advances with Non-Dilutive US Government Funding","url":"https://stock-news.laohu8.com/highlight/detail?id=2660646700","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660646700?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:04","pubTimestamp":1787058290,"startTime":"0","endTime":"0","summary":"Daré Bioscience DARE-HPV program advances with non-dilutive US government fundingDaré Bioscience said its DARE-HPV program for persistent high-risk HPV is advancing with non-dilutive government fundin","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nNDL9RX6Np:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BQXX3D17.EUR","BK4007","IE00BN0W2W23.USD","BK4585","LU2210150020.SGD","BK4588","BK4584","LU2210149790.SGD","BK4112","BCDF","IE00BQXX3F31.USD","DARE","NDAQ","SG9999014005.SGD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","LU0314104364.USD","LU2095319765.USD","SG9999014013.SGD","SG9999014021.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660467776","title":"DarÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660467776","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660467776?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260818:nTUA3YN9JF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["DARE","BK4584","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660460749","title":"DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List","url":"https://stock-news.laohu8.com/highlight/detail?id=2660460749","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660460749?lang=en_us&edition=fundamental","pubTime":"2026-08-18 21:02","pubTimestamp":1787058120,"startTime":"0","endTime":"0","summary":"National recognition comes as Daré Bioscience advances a multi-product women’s health strategy across commercialization, clinical development and first-in-category innovationSAN DIEGO, Aug.  18, 2026 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/18/3346918/30757/en/dar%C3%A9-bioscience-ceo-sabrina-martucci-johnson-named-to-forbes-2026-50-over-50-innovation-list.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0630314457.HKD","BK4585","LU0106261612.USD","LU0256331488.USD","FXG","BK4588","BK4189","DAR","LU0345780950.USD","LU0012050646.USD","LU1721429402.USD","LU1803068623.USD","LU1721429741.USD","BK4584","DARE","LABU","LU2308191902.HKD","LU0345781412.USD","LU2380233275.USD","BK4007","LU2211817866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660432587","title":"Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2660432587","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660432587?lang=en_us&edition=fundamental","pubTime":"2026-08-18 04:26","pubTimestamp":1786998405,"startTime":"0","endTime":"0","summary":"Veru Chief Scientific Officer Gary Barnette acquires $4,841.82 in common sharesVeru: Chief Scientific Officer K Gary Barnette bought 1,800 common shares at USD 2.69 each.Directly owned common shares r","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL8W9cTG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Veru Chief Scientific Officer Gary Barnette Acquires $4,841.82 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VERU","BK4007","BK4183","BK4557","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660820480","title":"Daré Bioscience Prices USD 6 Million Registered Direct Offering at USD 1.37 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2660820480","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660820480?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:36","pubTimestamp":1786970176,"startTime":"0","endTime":"0","summary":"Daré Bioscience prices USD 6 million registered direct offering at USD 1.37 per shareDaré Bioscience priced a registered direct offering of 4,379,581 common shares, or pre-funded warrants, at USD 1.37","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL9P7kcp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DARE","BK4007","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660655484","title":"Teva price target raised to $42 from $40 at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2660655484","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660655484?lang=en_us&edition=fundamental","pubTime":"2026-08-17 18:59","pubTimestamp":1786964399,"startTime":"0","endTime":"0","summary":"Barclays raised the firm’s price target on Teva (TEVA) to $42 from $40 and keeps an Overweight rating on the shares post the Q2 report. The firm se...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-42-from-40-at-barclays-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-price-target-raised-to-42-from-40-at-barclays-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4584","LU1983299246.USD","BK4007","TEVA","BK4566","BK4559","BK4585","BK4557","BK4588","BK4596","LU2324357040.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659827176","title":"Analysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DARE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659827176","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659827176?lang=en_us&edition=fundamental","pubTime":"2026-08-16 02:30","pubTimestamp":1786818607,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Belite Bio, Inc. ADR (BLTE) and Daré Bioscience (DAR...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-and-dare-bioscience-dare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-belite-bio-inc-adr-blte-and-dare-bioscience-dare-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["DIVL","BK4007","ARMH","HCSG","CVY","BK4137","DINT","SAPH","BK4581","LU0128526141.USD","BLTE","APIE","AADR","XBI","LU0029874061.USD","BK4584","XLV","DARE","BK4585","BK4588","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659135121","title":"Femasys Inc Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659135121","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659135121?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:59","pubTimestamp":1786741167,"startTime":"0","endTime":"0","summary":"Femasys Inc reports results for the quarter ended June 30 - Earnings SummaryFemasys IncFEMY.OQreported a quarterly adjusted loss of $1.55 per share for the quarter ended June 30, higher than the same ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL8N44B1L9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4539","BK4584","FEMY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659129844","title":"Evofem Q2 FY26 Net Loss Widens to $8.55 Million; Net Product Sales Fall 45% to $2.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659129844","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659129844?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:13","pubTimestamp":1786738420,"startTime":"0","endTime":"0","summary":"Evofem Q2 FY26 net loss widens to $8.55 million; net product sales fall 45% to $2.63 millionEvofem posted Q2 net product sales of $2.63 million, down 45% year over year.Cost of goods sold fell 32% to ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL24jwrp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","EVFM","BK4584"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126762","title":"Femasys Q2 Net Loss Narrows 2.55% to $4.47 Million; Net Sales Drop 18.9% to $331,827","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126762","media":"Reuters","labels":["executive","shareholding","corporation","dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126762?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:06","pubTimestamp":1786738006,"startTime":"0","endTime":"0","summary":"Femasys Q2 net loss narrows 2.55% to $4.47 million; net sales drop 18.9% to $331,827Femasys posted a Q2 net loss of USD 4.47 million, or USD 1.33 per share, versus a year-earlier net loss of USD 4.59 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nNDL4GywSL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,shareholding,corporation,dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","FEMY","IE00BKPKM429.USD","BK4539","BK4112","BCDF","IE00B3QW5Z07.USD","BK4588","IE00BGHQF748.EUR","LU2095319765.USD","LU2210150020.SGD","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","BK4584","NDAQ","IE00BN0W2W23.USD","SG9999014039.USD","LU0314104364.USD","SG9999014013.SGD","SG9999014021.USD","BK4082","SG9999014005.SGD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659126229","title":"Femasys Announces Financial Results for Quarter Ended June 30, 2026 and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659126229","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659126229?lang=en_us&edition=fundamental","pubTime":"2026-08-15 04:05","pubTimestamp":1786737901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nTUA4QFSV6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","FEMY","BK4584","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659123743","title":"Dare Bioscience Prices $6 Million Registered Direct Offering; Shares Fall","url":"https://stock-news.laohu8.com/highlight/detail?id=2659123743","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659123743?lang=en_us&edition=fundamental","pubTime":"2026-08-15 01:25","pubTimestamp":1786728312,"startTime":"0","endTime":"0","summary":"Dare Bioscience (DARE) said Friday it priced a registered direct offering of 4.4 million shares, or pre-funded warrants in lieu thereof, at $1.37 per share, with gross proceeds expected to be about $6","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4584","DARE","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":54,"code":"91000000","status":"200"}]}}